Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
18.07B
Market cap18.07B
Price-Earnings ratio
14.16
Price-Earnings ratio14.16
Dividend yield
Dividend yield
Average volume
1.92M
Average volume1.92M
High today
$93.28
High today$93.28
Low today
$90.34
Low today$90.34
Open price
$92.08
Open price$92.08
Volume
4.39M
Volume4.39M
52 Week high
$112.29
52 Week high$112.29
52 Week low
$53.56
52 Week low$53.56

Stock Snapshot

Incyte(INCY) stock is priced at $90.50, giving the company a market capitalization of 18.07B. It carries a P/E multiple of 14.16.

As of 2026-03-22, Incyte(INCY) stock has fluctuated between $90.34 and $93.28. The current price stands at $90.50, placing the stock +0.2% above today's low and -3.0% off the high.

Incyte(INCY) shares are trading with a volume of 4.39M, against a daily average of 1.92M.

During the past year, Incyte(INCY) stock moved between $53.56 at its lowest and $112.29 at its peak.

During the past year, Incyte(INCY) stock moved between $53.56 at its lowest and $112.29 at its peak.

INCY News

TipRanks 3d
Top Incyte Executive Makes Major Move With Fresh Insider Stock Sale

New insider activity at Incyte ( (INCY) ) has taken place on March 19, 2026. In a notable insider move at Incyte, President of R&D Pablo Cagnoni has sold 18,66...

TipRanks 3d
Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial

Incyte (INCY) announced an update on their ongoing clinical study. The Phase 1 trial “A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants Wi...

Simply Wall St 5d
Assessing Incyte Valuation As Short Term Returns Soften But Longer Term Gains Remain Strong

Incyte (INCY) has been drawing fresh attention after recent share price moves, with the stock showing mixed returns over the past week, month, and past 3 months...

Assessing Incyte Valuation As Short Term Returns Soften But Longer Term Gains Remain Strong

Analyst ratings

50%

of 28 ratings
Buy
39.3%
Hold
50%
Sell
10.7%

More INCY News

Simply Wall St 6d
How Diverging Zynyz Outcomes In Cancer Trials At Incyte Have Changed Its Investment Story

In early March 2026, Incyte reported a U.S. FDA Complete Response Letter for an additional lung cancer indication of Zynyz due to compliance issues at a third‑p...

How Diverging Zynyz Outcomes In Cancer Trials At Incyte Have Changed Its Investment Story
TipRanks 6d
Incyte downgraded to Hold from Buy at Jefferies

Jefferies analyst Faisal Khurshid downgraded Incyte (INCY) to Hold from Buy with a price target of $94, down from $120, after assuming coverage of the name. The...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.